Amgen and kyowa kirin announce top-line results from rocatinlimab phase 3 ascend long-term extension study in adults with moderate to severe atopic dermatitis

Thousand oaks, calif. and tokyo , sept.
TOP Ratings Summary
TOP Quant Ranking